Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 431 participants.

Also called NCT01257451

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 431 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01257451
Other papers using this trial's data
  • Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study Lancet (London, England), 2013-08-03 DOI, PubMed 23706759

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Belgium, Bulgaria, Finland, Germany, Slovakia, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01257451. Randomized; quadruple masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2012-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Vildagliptin
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01257451
Content hash
e673635545577cb975cf3489aeac957e99d032d21a34865fc75d8ae0b1c50209